Ascletis Pharma continues buyback, using new HK$500m mandate

Ascletis Pharma Inc. filed its Next Day Disclosure Return on December 16, 2025, detailing recent changes in its issued and treasury shares. As of December 16, 2025, the company's closing balance of issued shares (excluding treasury shares) stood at 991,874,320, with 7,084,210 treasury shares, resulting in a total of 998,958,530 issued shares.

The report highlights multiple share repurchases for cancellation throughout 2025. On December 16, 2025, Ascletis Pharma repurchased 200,000 ordinary shares on the Exchange at prices ranging from HKD 12.84 to HKD 13.47, totaling an aggregate price of HK$2,609,890. These repurchased shares are pending cancellation.

As of December 16, 2025, the company has repurchased a total of 4,786,000 shares under the mandate granted on May 22, 2025, which authorized the repurchase of 96,284,628 shares. This represents 0.4967% of the issued shares (excluding treasury shares) as at the date of the resolution. The moratorium period for any new share issues or sales of treasury shares after repurchases extends up to January 15, 2026.